Skip to content

Annexon ANNX Accounts Payable

Accounts Payable at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.03B+45.6%
Omeros logo
OmerosOMER
$5.37M+21.6%
Vor Biopharma logo
Vor BiopharmaVOR
$1.04M-72.1%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.51M-26.2%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$10.03M-43.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$7.52M+22.8%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's accounts payable?
Annexon (ANNX) reported accounts payable of $17.53M in Q1 2026.
How has Annexon's accounts payable changed year-over-year?
Annexon's accounts payable increased by 68.0% year-over-year, from $10.44M to $17.53M.
What is the long-term trend for Annexon's accounts payable?
Over 5 years (2020 to 2025), Annexon's accounts payable has grown at a 31.9% compound annual growth rate (CAGR), from $3.73M to $14.93M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.